Organogenesis Holdings: Q3 Earnings Insights

Shares of Organogenesis Holdings ORGO fell 3.61% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 258.33% over the past year to $0.19, which beat the estimate of ($0.08).

Revenue of $100,799,000 rose by 56.85% from the same period last year, which beat the estimate of $71,960,000.

Guidance

Organogenesis Holdings hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $311,000,000 and $314,000,000.

Conference Call Details

Date: Nov 09, 2020

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/xxf78hig

Price Action

52-week high: $8.34

52-week low: $2.47

Price action over last quarter: down 1.23%

Company Profile

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.